Get the Stockscreener App
1.575
2.50%
-0.035
Akebia Therapeutics Inc stock is traded at $1.575, with a volume of 1.05M.
It is down -2.50% in the last 24 hours and up +6.78% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.61
Open:
$1.63
24h Volume:
1.05M
Relative Volume:
0.26
Market Cap:
$417.95M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-5.625
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-5.44%
1M Performance:
+6.78%
6M Performance:
-56.76%
1Y Performance:
-17.38%
1-Day Range:
$1.56
$1.63
1-Week Range:
$1.56
$1.66
52-Week Range:
$1.445
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.575 | 427.24M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
125.41 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.48 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Quantisnow
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Finviz
Dow Update: Can Akebia Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Reactions & Accurate Intraday Trade Tips - moha.gov.vn
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Price Targets & Free Safe Capital Growth Stock Tips - Улправда
Why Akebia Therapeutics Inc. (AX9) stock gets analyst attention2025 Performance Recap & Stepwise Trade Signal Implementation - Улправда
What insider trading reveals about Akebia Therapeutics Inc. stockTreasury Yields & Accurate Intraday Trade Tips - Улправда
Is Akebia Therapeutics Inc. stock a buy for dividend growthPrice Action Analysis & Swing Trade Smarter With Data Insights - Bollywood Helpline
Volume Report: Can Akebia Therapeutics Inc. stock outperform in 2025 bull market - Улправда
Why Akebia Therapeutics Inc. stock is a must watch in 2025July 2025 Momentum & Fast Moving Market Watchlists - Улправда
Is Akebia Therapeutics Inc. stock safe for conservative investorsJuly 2025 Price Swings & Stepwise Swing Trade Plans - Улправда
How Akebia Therapeutics Inc. stock performs in weak economyWeekly Trend Summary & Daily Technical Forecast Reports - Улправда
Can Akebia Therapeutics Inc. stock deliver sustainable ROEEarnings Overview Report & Expert Curated Trade Setup Alerts - Улправда
Why Akebia Therapeutics Inc. stock is considered a top pickGlobal Markets & Free Community Supported Trade Ideas - Bölüm Sonu Canavarı
Is Akebia Therapeutics Inc. stock affected by interest rate hikes2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
Is Akebia Therapeutics Inc. (AX9) stock considered safe havenJuly 2025 Spike Watch & Accurate Trade Setup Notifications - DonanımHaber
Why Akebia Therapeutics Inc. (AX9) stock attracts HNW investorsVolume Spike & Weekly Momentum Stock Picks - Улправда
Is Akebia Therapeutics Inc. (AX9) stock a top pick for value investorsMarket Growth Review & Weekly Breakout Stock Alerts - Улправда
Will Akebia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Final Week & Community Consensus Trade Signals - Улправда
Aug Big Picture: Is Akebia Therapeutics Inc. stock safe for conservative investorsGold Moves & Safe Capital Growth Plans - Улправда
Is Akebia Therapeutics Inc. stock a buy on dipsWeekly Profit Recap & Consistent Return Strategy Ideas - Улправда
Activity Recap: What insider trading reveals about Akebia Therapeutics Inc. stockLayoff News & Detailed Earnings Play Alerts - Улправда
Why analysts recommend Akebia Therapeutics Inc. (AX9) stock2025 Earnings Impact & Advanced Swing Trade Entry Plans - ulpravda.ru
Market Moves: Is Akebia Therapeutics Inc. stock a buy on dipsAnalyst Downgrade & Capital Efficiency Focused Ideas - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Akebia Therapeutics Earnings Notes - Trefis
Akebia Therapeutics (FRA:AX9) OCF Margin % : 47.82% (As of Sep. 2025) - GuruFocus
Akebia Therapeutics announces establishment of rare kidney disease pipeline - MSN
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Akebia Therapeutics Inc AX9 stock attracts HNW investorsPortfolio Return Report & Reliable Entry Point Alerts - moha.gov.vn
Will Akebia Therapeutics Inc. (AX9) stock sustain dividend payoutsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - MSN
Is Akebia Therapeutics Inc. (AX9) stock testing key support2025 Key Highlights & Free Real-Time Volume Trigger Notifications - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Why Akebia Therapeutics Inc. (AX9) stock could be top winnerQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
HC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Buy Recommendation - MSN
BTIG Reiterates Buy Rating for Akebia Therapeutics (AKBA) | AKBA Stock News - GuruFocus
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Yahoo Finance
Akebia Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating for AKBA, Price Target Unchanged | AKBA Stock News - GuruFocus
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Is Akebia Therapeutics Inc a good long term investmentStock Market Trends & Access Free Tools and Start Investing - earlytimes.in
Can Akebia Therapeutics Inc. (AX9) stock sustain revenue momentumEarnings Overview Summary & Low Risk High Reward Ideas - Newser
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):